Index – National – Korányi Hospital also enters a clinical trial of favipiravir for coronavirus



[ad_1]

The Korányi National Institute of Pulmonology is also participating in the Hungarian-developed clinical trial of the favipiravir drug, the institution’s acting director general said in a video sent to the hospital’s MTI on Saturday. Krisztina Bogos emphasized that the study had answers to a number of questions, including the effectiveness of the drug in people with coronavirus infections, how safe it could be given, and at what stage of the infection the treatment was applied.

Gábor Takács, the hospital’s chief pharmacist, called favipiravir the last promising option in the treatment of coronavirus. He said the drug is not completely unknown, as it has already been used to treat the flu in other indications in Japan and China. However, recent data suggests that it is also effective in treating coronavirus.

According to Gábor Takács, a clinical trial lasts for months, is carried out according to a serious methodology and at the end a biostatistical evaluation is carried out. Because the study was recently launched, it takes several months for favipiravir to be truly effective. In any case, the results so far based on other clinical trials and data are extremely encouraging.

In addition to the coronavirus care, rehabilitation activities are also carried out in the hospital, said János Varga, head of the department. Patients who develop a lung transplant due to an advanced stage of chronic lung disease can be included in a rehabilitation program where they are cared for by internationally renowned professionals.

Patients in need can receive an objective evaluation and then present themselves to the Lung Transplant Tail Committee, he said.



[ad_2]